
<rss version="0.91">
    <channel>
        <title>Latest Articles from Immunology in Medicine</title>
        <description>Latest 6 Articles from Immunology in Medicine</description>
        <link>https://im.pensoft.net/</link>
        <lastBuildDate>Sun, 8 Nov 2026 08:40:53 +0000</lastBuildDate>
        <generator>Pensoft FeedCreator</generator>
        <image>
            <url>https://im.pensoft.net/i/logo.jpg</url>
            <title>Latest Articles from Immunology in Medicine</title>
            <link>https://im.pensoft.net/</link>
            <description><![CDATA[Feed provided by https://im.pensoft.net/. Click to visit.]]></description>
        </image>
	
		<item>
		    <title>TNF-α in acute ischemic stroke: a pilot study of early inflammatory changes and clinical associations</title>
		    <link>https://im.pensoft.net/article/219874/</link>
		    <description><![CDATA[
					<p>Immunology in Medicine 19(1): e219874</p>
					<p>DOI: 10.3897/im.19.e219874</p>
					<p>Authors: Maria Gevezova, Toma Tsvetanov, Margarita Koeva, Eleonora Kovacheva, Valentina Mihaylova, Valentin Dichev, Maria Kazakova, Victoria Sarafian</p>
					<p>Abstract: Introduction: Tumor necrosis factor-alpha (TNF-&alpha;) is a pro-inflammatory cytokine implicated in ischemic tissue injury and immune activation. However, its early circulating profile and associations with clinical and laboratory parameters in acute ischemic stroke (AIS) remain incompletely characterized. This pilot study investigated TNF-&alpha; levels at admission and 24 hours after intravenous thrombolysis (IVT), compared with healthy controls, and explored correlations with clinical and laboratory variables.Methods: Fifteen patients with AIS were assessed. TNF-&alpha; concentrations were measured at admission and 24 hours after IVT and compared with those in age- and sex-matched healthy controls. Correlations between TNF-&alpha;, biochemical and hematological parameters, and neurological severity assessed by the National Institutes of Health Stroke Scale (NIHSS) were evaluated using Spearman&rsquo;s rank correlation.Results: TNF-&alpha; levels were significantly elevated in patients with AIS compared with healthy controls, whereas no significant difference was observed between admission and 24-hour post IVT measurements. TNF-&alpha; correlated positively with triglycerides (&rho; = 0.600) and bleeding time (&rho; = 0.617), and negatively with creatinine (&rho; = &minus;0.834). NIHSS correlated positively with the platelet-to-lymphocyte ratio (PLR; &rho; = 0.572) and negatively with the absolute monocyte count (&rho; = &minus;0.570).Conclusion: This pilot study identified elevated circulating TNF-&alpha; in AIS without a detectable change at 24 hours after IVT. Exploratory correlations linked inflammatory, metabolic, hematological, and clinical parameters. These preliminary findings require validation in larger cohorts.</p>
					<p><a href="https://im.pensoft.net/article/219874/">HTML</a></p>
					
					<p><a href="https://im.pensoft.net/article/219874/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Mon, 2 Nov 2026 14:17:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Beyond clinical improvement: a pilot study on cytokine and ultrasonographic changes following Tofacitinib treatment in Rheumatoid arthritis</title>
		    <link>https://im.pensoft.net/article/220215/</link>
		    <description><![CDATA[
					<p>Immunology in Medicine 19(1): e220215</p>
					<p>DOI: 10.3897/im.19.e220215</p>
					<p>Authors: Valentina Mihaylova, Konstantin Batalov, Rositsa Karalilova, Anastas Batalov, Victoria Sarafian, Maria Kazakova</p>
					<p>Abstract: Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation and progressive joint damage. Interleukin-1 beta (IL-1&beta;) and interleukin-6 (IL-6) contribute to its pathogenesis, while musculoskeletal ultrasound provides valuable information about joint inflammatory activity. The aim of the study was to evaluate changes in IL-1&beta; and IL-6 protein and gene expression and their correlations with clinical and ultrasonographic disease activity in RA patients before and after Tofacitinib treatment. Methods: Fourteen patients with RA were evaluated at baseline and after Tofacitinib treatment. Disease activity was assessed using the 28-joint Disease Activity Score (DAS28) and the seven joint Global Ultrasound Score (GUS7). Plasma cytokine concentrations were measured using enzyme-linked immunosorbent assays (ELISA), and gene expression in peripheral blood cells was assessed by qPCR. Results: After six months, median DAS28 decreased from 5.80 to 3.31 (p&lt;0.001), while GUS7 decreased from 20.0 to 11.0 (p=0.002). Plasma IL-6 concentrations decreased significantly from 7.83 to 0.06 pg/mL (p=0.020). No significant changes were observed in plasma IL-1&beta; concentrations (p=0.445) or IL1-&beta; and IL-6 gene expression (p=0.922 and p=1.0, respectively). DAS28 and GUS7 were positively correlated at baseline (&rho;=0.890, p&lt;0.001) and after treatment (r=0.689, p=0.006). Conclusion: Tofacitinib treatment was associated with improved clinical and ultrasonographic disease activity and reduced plasma IL-6 concentrations. The absence of significant changes in IL-1&beta; concentrations and cytokine gene expression highlights the complexity of inflammatory regulation in RA. Combined clinical, imaging, and molecular assessments may provide complementary information on treatment response.</p>
					<p><a href="https://im.pensoft.net/article/220215/">HTML</a></p>
					
					<p><a href="https://im.pensoft.net/article/220215/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Thu, 29 Oct 2026 10:58:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Immunology of the male reproductive system - from testicular immune privilege to seminal plasma-induced reproductive tolerance</title>
		    <link>https://im.pensoft.net/article/215492/</link>
		    <description><![CDATA[
					<p>Immunology in Medicine 19(1): e215492</p>
					<p>DOI: 10.3897/im.19.e215492</p>
					<p>Authors: Natalia Grozdanova, Zdravko Kamenov</p>
					<p>Abstract: Male reproduction poses a distinctive immunological problem. Meiosis and post-meiotic differentiation generate germ-cell antigens after central self-tolerance has been established, yet these antigens must be protected without rendering the reproductive tract defenseless against infection. The solution is not simple sequestration. It is a spatially organized and dynamically regulated immune state created by the blood-testis barrier, Sertoli and Leydig cells, peritubular myoid cells, tissue-resident macrophages, dendritic cells, lymphocytes, soluble mediators, endocrine signals and local metabolic programs. This state permits robust spermatogenesis while retaining context-dependent innate and adaptive responses. Beyond the testis, the epididymis and accessory glands add further layers of antimicrobial defense and tolerance. Seminal plasma carries cytokines, prostaglandins, extracellular vesicles and paternal antigens into the female reproductive tract, where it initiates a controlled inflammatory response followed by antigen-specific immune adaptation. Transforming growth factor beta (TGF-&beta;) is prominent in this signaling network and, together with prostaglandin E (PGE) and other seminal mediators, contributes to dendritic-cell conditioning, leukocyte recruitment and expansion of regulatory T cells (Tregs). This review integrates the cellular and molecular basis of immune privilege in the male reproductive tract with the immunomodulatory function of semen at conception. It also considers how infection, sterile inflammation, autoimmunity, metabolic disease and disruption of barrier integrity impair spermatogenesis and sperm quality. The male reproductive system is best understood not as an immunologically isolated organ but as one component of a bidirectional immunological interface that links paternal physiology to maternal tolerance and reproductive outcome.</p>
					<p><a href="https://im.pensoft.net/article/215492/">HTML</a></p>
					
					<p><a href="https://im.pensoft.net/article/215492/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Review Article</category>
		    <pubDate>Mon, 5 Oct 2026 17:00:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>Correlation between virtual crossmatch, flow cytometric crossmatch and donor-specific alloantibodies in pretransplant evaluation for hematopoietic stem cell transplantation </title>
		    <link>https://im.pensoft.net/article/204987/</link>
		    <description><![CDATA[
					<p>Immunology in Medicine 19(1): e204987</p>
					<p>DOI: 10.3897/im.19.e204987</p>
					<p>Authors: Petya Yankova, Anastassia Mihaylova, Angela Antonova, Mariana Dimitrova, Elissaveta Naumova</p>
					<p>Abstract: Introduction: Donor-specific HLA antibodies (DSAs) have an adverse effect on engraftment after HLA- mismatched hematopoietic stem cell transplantation (HSCT). The presence of DSAs and flow cytometric crossmatch (FCXM) play an increasingly important role in donor selection.Aim: The aim of this study was to evaluate the correlation between virtual crossmatch (VXM), physical FCXM (PXM) and DSAs for assessing alloimmune reactivity before HSCT.Materials and methods: Forward (donor lymphocytes with recipient serum), reverse (patient lymphocytes with donor serum) and autologous FCXM were performed. HLA antibodies specificities were determined using Luminex technology (Single Antigen Beads Assay&ndash;SAB) and accepted as positive at mean fluorescence intensity (MFI) &ge;1500. VXM was determined based on the donor HLA and recipient DSAs.Results: Of the 129 candidates for allogeneic HSCT, anti-HLA antibodies were detected in 43 (33.3%) of them. DSAs were present in 25 patients. Out of 340 FCXM performed 73 were positive. Best VXM prediction (90.6%) was observed for the negative samples. Positive virtual T-cell crossmatches correspond to the PXM in 87.5% (28/32). The lowest (29/45, 64.4%) was the correlation in the B-cell crossmatches. The MFI values predictive for a positive FCXM are highest for HLA-DR and -DQ antibodies (MFI &ge;5000). Conclusion: The correlation between VXM and FCXM depends on both the MFI value and the locus specificity of the DSAs. VXM could be taken into consideration in the process of donor search. The decision to transplant should be based on DSAs and a physical FCXM.</p>
					<p><a href="https://im.pensoft.net/article/204987/">HTML</a></p>
					
					<p><a href="https://im.pensoft.net/article/204987/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Short Communication</category>
		    <pubDate>Mon, 27 Jul 2026 12:15:48 +0000</pubDate>
		</item>
	
		<item>
		    <title>Predictive value of baseline eosinophil counts for immune-related adverse events in metastatic NSCLC treated with immune checkpoint inhibitors</title>
		    <link>https://im.pensoft.net/article/202021/</link>
		    <description><![CDATA[
					<p>Immunology in Medicine 19(1): e202021</p>
					<p>DOI: 10.3897/im.19.e202021</p>
					<p>Authors: Antoan Garev, Tsvetelina Ignatov, Nikolay Garev, Nikolay Evstatiev, Konstantina Panova-Kapitanova, Zornitsa Gorcheva, Mihaela Atanasova</p>
					<p>Abstract: Background: Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of metastatic non-small cell lung cancer (mNSCLC). Immune-related adverse events (irAEs) remain a significant challenge, and reliable biomarkers for predicting their occurrence and severity are lacking. Objective: To evaluate whether baseline eosinophil counts are associated with the onset and severity of immune-related adverse events in patients with metastatic non-small cell lung cancer treated with immunotherapy.Materials and methods: This retrospective single-center study included 52 patients with mNSCLC treated with ICIs. Baseline absolute eosinophil counts were collected prior to treatment initiation. Patients were categorized into three groups based on the highest grade of toxicity observed during therapy: no irAEs, grade 1&ndash;2 irAEs, and grade 3&ndash;5 irAEs, according to CTCAE v5.0. Comparisons between groups were performed using the Kruskal&ndash;Wallis test with post-hoc pairwise analysis.Results: Among the included patients, 28 (53.8%) experienced no irAEs, 15 (28.8%) developed grade 1&ndash;2 irAEs, and 9 (17.3%) developed grade 3&ndash;5 irAEs. Baseline eosinophil counts increased progressively across toxicity groups, with median values of 110 cells/&micro;L (IQR 67.5&ndash;242.5) in patients without irAEs, 180 cells/&micro;L (IQR 115&ndash;410) in those with mild irAEs, and 470 cells/&micro;L (IQR 380&ndash;650) in patients with severe irAEs. The overall difference between groups was statistically significant (Kruskal&ndash;Wallis test, p = 0.026). Pairwise comparisons showed significantly higher eosinophil levels in patients with grade 1&ndash;2 (p = 0.034) and grade 3&ndash;5 irAEs (p = 0.019) compared with patients without irAEs.Conclusion: Higher baseline eosinophil counts were associated with both the occurrence and severity of immune-related adverse events in patients with metastatic non-small cell lung cancer receiving immunotherapy. Baseline eosinophils represent an accessible and clinically applicable biomarker that may support pretreatment risk stratification and individualized toxicity monitoring. Prospective validation is warranted.</p>
					<p><a href="https://im.pensoft.net/article/202021/">HTML</a></p>
					
					<p><a href="https://im.pensoft.net/article/202021/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Research Article</category>
		    <pubDate>Mon, 13 Jul 2026 09:01:00 +0000</pubDate>
		</item>
	
		<item>
		    <title>The role of flow cytometric assessment of TRBC1/2 expression in ruling out hematologic malignancy in a patient with EBV/CMV induced lymphoproliferation: A case report</title>
		    <link>https://im.pensoft.net/article/202240/</link>
		    <description><![CDATA[
					<p>Immunology in Medicine 19(1): e202240</p>
					<p>DOI: 10.3897/im.19.e202240</p>
					<p>Authors: Georgi Vasilev, Rositsa Vladimirova, Maria Muhtarova, Milan Jagurinoski, Margarita Guenova</p>
					<p>Abstract: Background:  In a clinical setting, some atypical cases of mononucleosis accompanied by marked lymphocytosis featuring atypical pleomorphic morphology and lymphadenomegaly, raise hematological red flags and could  create a diagnostic challenge.Case presentation:  We report a case of an 18-year-old male presenting with bilateral lymphadenopathy limited to the cervical region, and significant absolute lymphocytosis (12.12 x109/L). Biochemical markers showed elevated  LDH and transaminases, while virological analysis confirmed concurrent primary EBV and CMV infection, but lacked the classical EBV-associated triad: fever, pharyngitis and generalized lymphadenomegaly. Morphological assessment of the peripheral blood ident ified atypical lymphocytes. Multiparametric flow cytometry revealed a massive expansion of activated (CD38+/HLA-DR+) CD8+ T-cytotoxic lymphocytes with a severely inverted CD4/CD8 ratio of 0.1. The definitive exclusion of malignancy was achieved using the n ovel TCR&beta;C1/TCR&beta;C2 flow cytometric analysis, which demonstrated a polytypic distribution (38%/59%), confirming a reactive polyclonal proliferation.Conclusion:  Integrated diagnostic approaches are essential in cases of significant viral-induced lymphocytos is. TCR&beta;C1/2 typing serves as a rapid and objective tool to confirm polyclonality, allowing for the early exclusion of T-cell neoplasms and the definitive diagnosis of reactive lymphoproliferation .</p>
					<p><a href="https://im.pensoft.net/article/202240/">HTML</a></p>
					
					<p><a href="https://im.pensoft.net/article/202240/download/pdf/">PDF</a></p>
			]]></description>
		    <category>Short Communication</category>
		    <pubDate>Mon, 13 Jul 2026 09:00:30 +0000</pubDate>
		</item>
	
	</channel>
</rss>
	